{"entity":{"id":"nct04335669","kind":"trial","name":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","aka":[],"tldr":"A phase 3 trial of epirubicin, cyclophosphamide, paclitaxel / nab-paclitaxel, carboplatin and other drugs in triple-negative breast cancer, run by Lund University Hospital, active but no longer recruiting.","summary":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC is a phase 3, randomised interventional study registered as NCT04335669 by Lund University Hospital, with a registry enrolment figure of 325 participants, started 2019-12-20 and due to reach its primary completion in 2035-09. Interventions recorded: epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab; epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab. Conditions listed: Breast Cancer; Triple Negative Breast Neoplasms. Sites: Denmark, Sweden. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04335669","url":"https://clinicaltrials.gov/study/NCT04335669"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["epirubicin","cyclophosphamide","paclitaxel","carboplatin","pembrolizumab","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04335669","phase":"3","setting":"A Translational Randomized Phase III Study Exploring the Effect of the Addition of Capecitabine to Carboplatine Based Chemotherapy in Early \"Triple Negative\" Breast Cancer","sponsor":"Lund University Hospital","enrolled":325,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04335669/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}